QIAGEN's CEO Discusses 1Q 2012 Results - Earnings Call Transcript

QIAGEN N.V. (QGEN)

1Q 2012 Earnings Call

April 24, 2012 9:30 a.m. ET

Executives

Albert Fleury – Director Investor Relations North America

Peer Schatz – Chief Executive Officer

Roland Sackers – Chief Financial Officer

John Gilardi – Vice President, Corporate Communications and Investor Relations

Analysts

Daniel Wendorff - Commerzbank

Tycho Peterson - JP Morgan

Quintin Lai - Baird

Martin Wales - UBS

Zarak Khurshid - Wedbusch

Travis - Macquarie

Bill Bonello - RBC Capital Markets

Brian Weinstein - William Blair & Company

Peter Lawson - Mizuho Securities

Dan Leonard - Leerink Swann

Presentation



Operator

Compare to:
Previous Statements by QGEN
» QIAGEN's CEO Discusses Q4 2011 Results - Earnings Call Transcript
» QIAGEN's CEO Hosts Investor Day - Conference Call Transcript
» QIAGEN's CEO Discusses Q3 2011 Results - Earnings Call Transcript
» Qiagen's CEO Discusses Q2 2011 Results - Earnings Call Transcript

Ladies and gentlemen, thank you for standing by. Welcome to QIAGEN N.V. investor and analyst conference call on the Q1 results 2012. (Operator instructions) I would not like to turn the conference over to Albert Fleury, Director Investor Relations and Corporate Finance NA. Please go ahead, sir.

Albert Fleury

Thank you. Good afternoon and good morning to you in the U.S. and welcome to the QIAGEN conference call to discuss our latest quarterly results. Joining me on the call this morning are Peer Schatz, Chief Executive Officer, Roland Sackers, Chief Financial Officer, and John Gilardi, Vice President, Corporate Communications and Investor Relations. A copy of this announcement and the presentation for this conference can be downloaded from the Investor Relation’s section of our home page at www.qiagen.com.

Before I turn the call over to Peer, please keep in mind that the following discussion and responses to your questions reflect management’s view as of today, April 26, 2012. As we share information to help you better understand our business, we will make statements and provide responses that state our intentions, beliefs, expectations or predictions of the future. These constitute forward-looking statements for the purpose of the Safe Harbor provisions. These involve certain risks and uncertainties that could cause QIAGEN’s actual results to differ materially from those projected. QIAGEN disclaims any intention or obligation to revise any forward-looking statements. For a complete description of the risks and uncertainties, please refer to our Form 20-F filed with the U.S. Securities and Exchange Commission.

1 2 3 Next › Last »